FDA-approved therapies for metastatic hormone-sensitive prostate cancer (mHSPC)

[Tall_Allen]

With the FDA approval of Erleada for this indication, I updated my blog about available options for mHSPC. I also included Xtandi in anticipation of its approval soon.

pcnrv.blogspot.com/2017/06/...

[Schwah]

Couple of things TA. First you say “ only 3% of new patients are newly diagnosed with metastatic, hormone-sensitive prostate cancer”. Is there a difference in treatment between “newly diagnosed” and those who have had primary treatment and are later diagnosed with a recurrence that is metastatic and hormone sensitive? Secondly, from looking at your hazard ratio’s, so far it looks like it’s Xandi is winning the race right?

Schwah

[Tall_Allen in reply to Schwah]

1. Recurrent is different. The STAMPEDE trials include a group of recurrent patients, but the other trials do not. I focussed on newly diagnosed.

2. No -you cannot compare across studies. That's why I wrote: "One should resist the temptation to compare HRs across studies. Each study had different patient characteristics, and PSA screening policies differ markedly in those countries. In fact, a recent analysis of the STAMPEDE outcomes of men who were randomly assigned to either Zytiga or docetaxel found that there was no difference in survival between the two treatments "

I probably should not have shown the HRs - just noted whether the effect was statistically significant. I'll edit when I get a chance. Thanks for bringing up the issue.

[Magnus1964]

Great information, thanks for posting this.